Kenna M. Shaw

TL;DR: Systematic studies of more than 25,000 cancer genomes will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.

TL;DR: Integrated proteogenomic analysis provides functional context to interpret genomic abnormalities and affords a new paradigm for understanding cancer biology.

TL;DR: A view of how the somatic genome drives the cancer proteome and associations between protein and post-translational modification levels and clinical outcomes in HGSC is provided.

TL;DR: The integration of mass spectrometry-based proteomics with next-generation DNA and RNA sequencing profiles tumors more comprehensively underscores the potential of proteogenomics for clinical investigation of breast cancer through more accurate annotation of targetable pathways and biological features of this remarkably heterogeneous malignancy.

TL;DR: In this article, a detailed analysis of the molecular components and underlying mechanisms associated with ovarian cancer was provided, such as how different copy-number alterna-tions in the Proteome, the proteins associated with chromosomal instability, the sets of signalingpathways that diverse genome rearrangements converge on, and the ones associated with short overall survival.